Vascularized composite allotransplantation (VCA) is a surgical approach for the clinical management of non-salvagable injuries. Tissue rejection is a major issue for patients receiving VCA. Tacrolimus is the most common immunosuppressant employed to minimize tissue rejections in VCA. The safety and efficacy of tacrolimus, which has a narrow therapeutic window is particularly sensitive to proper maintenance of drug plasma levels. With the currently available tacrolimus assays, plasma level monitoring can only be performed in a clinical laboratory setting. Development of a self-test would allow patients receiving VCA to monitor plasma tacrolimus levels at home, thereby reducing logistical burdens on both the health care system and the patients. Moreover, a home test will allow more frequent monitoring, thereby minimizing incidence of tissue rejections and adverse effects. Lynntech proposes to develop an innovative non-powered, portable microfluidic format that integrates sample preparation and assay performance within the same cartridge. A smartphone-based application allows data interpretation, storage and dissemination via wireless connectivity. Thus, Lynntechs platform represents an end-to-end solution that enables target biomolecule identification/quantification in a rapid (~20 minutes) and inexpensive (immunosuppressant,vascularized composite allotransplantation,tacrolimus,Therapeutic Drug Monitoring,at-home test
